A University of Alberta research team has identified a new drug target to treat harmful E. coli bacteria—which cause nearly 250,000 deaths a year from urinary tract infections (UTI) and are becoming increasingly resistant to antibiotics. Their recently published research in Nature Communications shows how the protease known as GlpG, located in the cellular membrane, is central to the bacteria's ability to infect human cells and resist treatment.

A University of Alberta research team has identified a new drug target to treat harmful E. coli bacteria—which cause nearly 250,000 deaths a year from urinary tract infections (UTI) and are becoming increasingly resistant to antibiotics. Their recently published research in Nature Communications shows how the protease known as GlpG, located in the cellular membrane, is central to the bacteria’s ability to infect human cells and resist treatment.

From Biology News - Evolution, Cell theory, Gene theory, Microbiology, Biotechnology via This RSS Feed.